|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Hormonal Contraceptives - New directions in a competitive market
Datamonitor, Nov 2006, Pages: 99
The hormonal contraceptive market grew by 4.2% from 2004 to $5.0 billion in 2005.
Market growth was driven in part by the strong uptake of Schering AG's Yasmin and Organon's NuvaRing which fulfill key strategies: additional indications and alternative delivery modes.
Market growth is not expected to falter if companies employ these lifecycle strategies which promote uptake in a competitive market.
Scope
- Identification of the key products and players in the seven major markets and their strategies for success
- Benchmarking lifestyle management strategies for hormonal contraceptives
- Assessment of the potential of the switch from prescription to over-the-counter opportunity
- Examination of the pipeline and future directions of the market, such as the elusive but potentially lucrative male hormonal contraception opportunity.
Highlights
Despite the slow growth of the Japanese market, opinion leaders believe it can be enlivened by the introduction of innovative delivery methods and by following the sales and marketing strategies successfully employed by Wyeth in Japan.
Should hormonal contraceptives become available over the counter, several companies are suitably placed to enter the new market, including those with two strong brands and those facing patent expiry on a key portfolio product.
Additional indications provide a key growth opportunity. The acne market is saturated with contraceptives and the Yasmin family is synonymous with premenstrual symptoms. However, estrogen deficiency and uterine fibroid indications are commercially attractive.
Reasons to Purchase
- Understand key opinion leaders views on topical issues in the hormonal contraceptive market
- Explore the avenues open to a company intending to optimize brand sales in a mature and competitive market
- Determine the strengths of and challenges to products with innovative delivery mechanisms, dosing regimens, and additional indications
Customers who bought this item also bought
Commercial Insight: Hormonal Contraceptives - Look Beyond Oral Contraception for a Competitive Edge
Strategic Perspectives 2001: Hormonal contraceptives
Hormonal Contraceptives Market Forecast
The Global Market For Hormonal Contraceptives and Infertility Drugs, 2005-2012
Hormonal Contraception: Market Update - Surviving the Generic Threat
Contraceptives - Global Strategic Business Report
Oral Contraceptives & Condom Market: An Analysis
Women's Health Series: How Have New Oral Contraceptives Changed the Market?
Contraceptives in the US
Contraceptives in the United States 2008
The 2009 Report on Non-Hormonal Anti-Arthritics and Anti-Inflammatory Agents: World Market Segmentation by City
The 2009-2014 World Outlook for Non-Hormonal Anti-Arthritics and Anti-Inflammatory Agents
|
|
|
|
